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Summary 
Purpose: Mutations in the SCN1A gene, which encodes the α1 subunit of voltage-gated 
sodium channels, cause generalized epilepsy with febrile seizures plus (GEFS+) and 
severe myoclonic epilepsy of infancy (SMEI). N1417H-Scn1a mutant rats are 
considered to be an animal model of human FS+ or GEFS+. To assess the 
pharmacological validity of this model, we compared the efficacies of 8 different 
antiepileptic drugs (AEDs) for the treatment of hyperthermia-induced seizures using 
N1417H-Scn1a mutant rats. Methods: AEDs used in this study included valproate, 
carbamazepine (CBZ), phenobarbital, gabapentin, acetazolamide, diazepam (DZP), 
topiramate, and potassium bromide (KBr). The effects of these AEDs were evaluated 
using the hot water model, which is a model of experimental FS. Five-week-old rats 
were pretreated with each AED and immersed in water at 45°C to induce 
hyperthermia-induced seizures. The seizure manifestations and 
video-electroencephalographic recordings were evaluated. Furthermore, the effects of 
each AED on motor coordination and balance were assessed using the balance-beam 
test. Key Findings: KBr significantly reduced seizure durations, and its anticonvulsant 
effects were comparable to those of DZP. On the other hand, CBZ decreased the seizure 
threshold. In addition, DZP and not KBr showed significant impairment in motor 
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coordination and balance. Significance: DZP and KBr showed potent inhibitory effects 
against hyperthermia-induced seizures in the Scn1a mutant rats, whereas CBZ exhibited 
adverse effects. These responses to hyperthermia-induced seizures were similar to those 
in patients with GEFS+ and SMEI. N1417H-Scn1a mutant rats may therefore be useful 
to test the efficacy of new AEDs against FS in GEFS+ and SMEI patients. 
 
Key words: Febrile seizure, animal models, Scn1a gene, Generalized epilepsy with 
febrile seizures plus, severe myoclonic epilepsy of infancy 
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Introduction  
Febrile seizures (FS) are the most common convulsive disorder affecting 2–5% of 
children between the ages of 6 months and 6 years (Verity et al., 1985; Hauser et al., 
1994; Offringa et al., 2001). Although most FS are benign, known as simple FS, and do 
not require treatment, 2–7% of patients with FS subsequently develop epilepsy (Baulac 
et al., 2004). Generalized epilepsy with febrile seizures plus (GEFS+) is a familial 
epileptic syndrome characterized by FS persisting beyond 6 years and subsequent 
development of various types of epilepsy, including generalized tonic-clonic, myoclonic, 
and absence seizures (Scheffer and Berkovic, 1997). In severe myoclonic epilepsy of 
infancy (SMEI; also known as Dravet syndrome), repetitive FS begin in the first year of 
life, and life-threatening status epilepticus is often provoked by fever. Therefore, 
appropriate treatment of FS is important for patients with GEFS+ and SMEI. 
Heterozygous mutations in SCN1A, a gene encoding the α1 subunit in voltage-gated 
sodium channels (NaV1.1), are responsible for GEFS+ and SMEI. Mutations in SCN1A 
account for 80% of SMEI cases and 10% of GEFS+ cases (Claes et al., 2001; Ohmori et 
al., 2002; Hattori et al., 2008). Developments in genetic engineering have enabled the 
generation of various genetically modified animals, and many researchers can now 
investigate pathology and new disease treatments using these animals.  
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Recently, Mashimo et al. generated Scn1a mutant rats (F344/NSlc-Scn1aKyo811) with 
the missense mutation, N1417H, using ENU mutagenesis (2008, 2010). These 
N1417H-Scn1a mutant rats are considered an animal model of human FS+ or GEFS+. 
Generally, animal models of human diseases are required to fulfill three criteria, namely 
face validity, construct validity, and predictive validity (Chadman et al., 2009). Face 
validity incorporates a conceptual analogy to the symptoms of the human disease. 
Homozygous N1417H-Scn1a mutant rats exhibited susceptibility to 
hyperthermia-induced seizures, and their seizures persisted over the age of 5 weeks, 
whereas WT rats were unaffected. (Mashimo, et al., 2010). Therefore, this model rat 
showed similar febrile seizures to those seen in patients with GEFS+ and SMEI. Second, 
construct validity incorporates a conceptual analogy to the cause of the human disease. 
These rats have an N1417H missense mutation in the causative SCN1A gene of GEFS+ 
and SMEI. N1417H was not detected in human patients, but the electrophysiological 
properties of N1417H share a common molecular basis of most of SMEI, and some  
GEFS+ patients. Namely, the recombinant N1417H-human SCN1A mutation was 
revealed to have a loss-of-function effect on Nav1.1, and the hippocampal neurons of 
these rats demonstrated impaired biophysical properties of inhibitory GABAergic 
neurons (Mashimo et al., 2010). We have confirmed that N1417H-Scn1a mutant rats 
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fulfilled these two criteria in our previous study. Here, we addressed the third criterion, 
predictive validity. It incorporates the specificity of responses to treatments that are 
effective in the human disease. We herein evaluated the efficacy of antiepileptic drugs 
(AEDs) on hyperthermia -induced seizures in the model rats. Potassium bromide (KBr), 
a traditionally prescribed AED, was found to be as effective as DZP, while CBZ showed 
adverse effects. These drug-mediated responses to hyperthermia-induced seizures in the 
new model rats were similar to those in patients with GEFS+ or SMEI. 
 
Materials and Methods 
Animals 
Male homozygous N1417H-Scn1a mutant rats (F344/NSlc-Scn1aKyo811) (National Bio 
Resource Project for the Rat in Japan, Kyoto University, Kyoto, Japan) were used to 
assess the effects of AEDs against hyperthermia-induced seizures. The susceptibility of 
wild-type rats to hyperthermia decreases with age, and therefore, these 5-week-old rats 
showed no indications of hyperthermia-induced seizures, whereas the homozygous 
N1417H-Scn1a mutant rats demonstrated generalized tonic-clonic seizures induced by 
hyperthermia until at least 10 weeks of age (Mashimo et al., 2010). The rats were 
maintained under standard laboratory conditions with a 12-h light/dark cycle and food 
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and water ad libitum. All experiments were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee of Okayama University. 
 
Induction of hyperthermia-induced seizures 
Experimental FS have been extensively studied in a well-established model, in which 
FS are evoked by exposing the rat pups (postnatalday 8–15) to heated air (Holtzman et 
al., 1981; Schuchmann et al., 2006), hot water jet on the heads (Ullal et al., 1996), or hot 
water bathing (Klauenberg and Sparber, 1984). We used hot water bathing from the 
view point of animal welfare, namely heated air requires longer exposure of the rats to 
hyperthermic environment and induces more severe seizures compared with hot water 
bathing (Supplementary Fig. 1). Induction of hyperthermia-induced seizures was 
performed as described previously, with slight modifications (Mashimo et al., 2010). 
Hyperthermia was induced by placing the rats in a 19.0 × 24.7 × 15.5 cm water bath 
(Thermo minder SD mini, Taitec, Japan) filled with water at 45°C to a depth of 6 cm 
(Fig. 1A). The rats were kept in the water for a maximum of 5 min or until a seizure 
occurred. We confirmed that immersing the rats in 37ºC and 40ºC water for 5 min did 
not evoke seizures (Supprementary Fig. 2). When a seizure occurred, the rats were 
immediately removed from the bath and monitored until they recovered. Rectal 
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temperature of the rats was measured immediately after seizure onset using a digital 
thermometer (BDT-100, Bioresearch Center, Japan) connected to rectal probe (Ret-2, 
Physitemp, USA). Each rat was assigned a score based on the most severe seizure 
observed. The seizure parameters were scored as follows: (0) no response; (1) head 
nodding with brief twitching movements (Fig. 1B); (2) repetitive myoclonic jerks with 
postural tone (Fig. 1C); (3) jumping and/or running fits (Fig. 1D); (4) generalized 
tonic-clonic seizure with loss of postural tone (Fig. 1E); and (5) death due to continuous 
convulsions. Seizure parameters were scored by an investigator who was blinded to the 
treatment received. All procedures were recorded using a video camera. 
 
Treatment with AEDs 
To assess the pharmacological validation of N1417H-Scn1a mutant rats, AEDs which 
have been established to be effective in patients with GEFS+ and SMEI were chosen. 
AEDs used in the present study included sodium valproate (VPA-Na; Sigma-Aldrich, 
Japan), phenobarbital sodium (PB-Na; Wako, Japan), diazepam (DZP; Wako, Japan), 
carbamazepine (CBZ; Sigma-Aldrich, Japan), acetazolamide sodium (AZA-Na; Diamox, 
Sanwa, Japan), potassium bromide (KBr; Wako, Japan), topiramate (TPM; Toronto 
Research Chemicals, Canada), and gabapentin (GBP; Toronto Research Chemicals, 
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Canada). VPA-Na, PB-Na, AZA-Na, KBr, and GBP were dissolved in saline. CBZ, 
DZP, and TPM were suspended in 10% polyethylene glycol 400 with saline. The rats 
were fasted overnight and orally administered each AED. Experimental conditions were 
determined based on the results of preliminary studies (Supplementary Fig. 3). As the 
appropriate range of each AED for the model rats is not known, we referred to the doses 
used to treat human epilepsy. The therapeutic range of each AED was determined 
according to previous literatures as follows; VPA, 40–120 µg/ml (Schmidt, 2009); CBZ, 
4–12 µg/ml (Eadie, 2001); PB, 10–40 µg/ml (Schmidt, 2009); GBP, 2–20 µg/ml 
(McLean, 1999); AZA, 10–20 µg/ml (Granero et al., 2007); DZP, 0.2–0.6 µg/ml (Ogutu 
et al., 2002); and KBr, 500–1500 µg/ml (Ryan and Baumann, 1999). In cases where the 
blood concentration did not reach the therapeutic range, a higher dose was administrated 
to achieve a concentration higher than the top of the therapeutic range of each AED. 
Seizures were induced when the blood concentration of each AED elevated to an 
adequate level. VPA-Na (200 mg/kg) was administered for 30 min; CBZ (200 mg/kg), 
120 min; PB-Na (50 mg/kg), 240 min; GBP (100 mg/kg), 90 min; AZA-Na (55 mg/kg), 
30 min; DZP (5 mg/kg), 15 min; TPM (80 mg/kg), 90 min; and KBr (1800 mg/kg), 90 
min before seizures were induced. Experimental conditions of DZP and TPM 
administration were determined based on previous studies (Ishihara et al., 2000; 
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Borowicz et al., 2003; Sendrowski et al., 2007). The temperature threshold was 
measured using the rectal temperature of the rats immediately after seizure onset, in 
addition to the duration of the seizure and the seizure severity score. After seizure 
termination, blood samples were obtained from the tail vein of the rats, and the blood 
concentration of each AED was then measured. Measurement of the blood 
concentrations of each AED was performed as described in Supplemental Methods. 
 
Electroencephalography 
Ictal electroencephalogram (EEG) patterns were also analyzed for four AEDs (AZA, 
TPM, DZP, and KBr) which exhibits remarkable therapeutic effects and CBZ, which 
may aggravate hyperthermia-induced seizures. At 4 weeks of age, the rats were 
implanted with electrodes for EEG recordings. Under pentobarbital sodium anesthesia 
(35 mg/kg, i.p.; Nembutal, Abbott Laboratories, USA), the rats were fixed to a 
stereotaxic apparatus (SR-5M, Narishige, Japan). Stainless steel screw electrodes (2.0 Ø 
× 0.6 × 1.7 mm; Fukuoka Seimitsu, Japan) were implanted bilaterally into the frontal 
cortex (AP: +0.5 mm; ML: ±3.0 mm from bregma) and occipital cortex (AP: −7.0 mm; 
ML: ±3.0 mm from bregma). In addition, a stainless steel screw implanted into the 
posterior end of the skull served as a reference electrode. This assembly was fixed to the 
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skull with dental cement (UNIFAST II, GC Dental Products, Japan). After a 1-week 
recovery period, cortical EEGs were recorded through electroencephalography 
(Neurofax EEG-1200, Nihon Koden, Japan). The duration of the seizure discharges 
between seizure onset and termination were analyzed.  
Balance-beam test 
Each AED has various side effects on the central nervous system, gastrointestinal 
organs, urinary tracts, and so on, especially following chronic use. In the present study, 
we only assessed the acute effects on motor coordination and balance because AEDs 
were administered as a single dose. This test was performed as described previously, 
with slight modifications (Carter et al., 1999; Perez et al., 2005). The beam was 105 cm 
long, 35 mm wide, and was elevated 100 cm above the ground. A black box (20 × 18 × 
30 cm) was set at one end of the beam as the goal. A bright light was situated opposite 
the goal box to encourage the rats to cross the beam (Fig. 5A). The rats were first 
trained to traverse the beam and were then tested. Crossing time and the number of 
footfalls were recorded. 
 
Statistical analysis 
Data are presented as mean ± SEM. Data analyses were performed using non-repeated 
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measures ANOVA with Dunnett’s post hoc test. Seizure severity scores were analyzed 
using the Kruskal–Wallis H test together with the Mann–Whitney U test, followed by 
the Bonferroni correction post hoc test. Statistical difference was defined as p < 0.05. 
 
Results 
Effects of AEDs on hyperthermia-induced seizures 
In order to evaluate which AEDs are effective against hyperthermia-induced seizures in 
Scn1a mutant rats, we induced seizures by immersing the rats pretreated with each AED 
in water at 45°C. The anticonvulsant effects of AEDs were assessed using 4 parameters: 
incidence of seizure; temperature threshold, calculated from the rectal temperature of 
the rats immediately after seizure onset; seizure duration; and seizure severity score. 
DZP and KBr, but no other AEDs, reduced the incidence rate of hyperthermia-induced 
seizures (Fig. 2A). PB, DZP, TPM, and KBr significantly increased the temperature 
threshold, whereas CBZ, GBP, and AZA decreased the threshold (Fig. 2B). All AEDs, 
except CBZ, significantly decreased the seizure duration (Fig. 2C). In particular, AZA, 
DZP, and KBr shortened the seizure duration dramatically (Fig. 2C). Although DZP and 
KBr tended to reduce the seizure severity scores, significant changes were not observed 
(Fig. 2D). 
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After seizure termination, blood samples were obtained from the tail vein of the rats, 
and blood concentrations of the AEDs were then measured. Blood concentrations of all 
AEDs, except those of DZP, increased over the therapeutic range (Table 1). Although 
the serum level of DZP did not reach the therapeutic range in the 5 mg/kg DZP-treated 
group, these rats showed ataxia and lethargy in the hot bath; therefore, the dose of DZP 
was not increased. We couldn’t exclude the possibility that higher doses of some of 
AEDs may have lead to the different results. 
 
Electroencephalography 
Ictal EEG patterns were examined in 5 AEDs (AZA, TPM, DZP, KBr and CBZ). 
Representative ictal EEG recordings from the rats are shown in Figs. 3 and 4A. It was 
observed that seizures began as tonic seizures with high frequency spikes, followed by 
clonic seizures (Fig. 4A). Hyperthermia-induced seizures in Scn1a mutant rats were 
often provoked as several recurrent seizures with a few seconds interval between the 
seizures. Before the second tonic-clonic seizure occurs, interictal spikes appear and 
gradually increase their amplitude. Between the first seizure and the second seizure, 
high amplitude spikes were associated with myoclonic jerks. We analyzed the duration 
of the seizure discharges on EEGs between seizure onset and termination (Fig. 4A). 
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AZA, DZP, and KBr significantly reduced the duration of the seizure discharges, 
whereas CBZ and TPM showed no significant changes (Fig. 4B).  
 
Balance-beam test 
Motor coordination and balance were examined using the balance-beam test for some of 
the AEDs which showed remarkable inhibitory effects on hyperthermia-induced 
seizures (Fig. 5A, B). Although control (i.e., untreated) rats walked along the beam with 
ease, motor deficits were observed in the PB- and DZP-treated groups (Fig. 5C, D). On 
the other hand, AZA and KBr did not affect motor coordination or balance (Fig. 5 C, 
D). 
 
Discussion 
In total, more than 600 mutations in the SCN1A gene have been identified in patients 
with SMEI and GEFS+. SCN1A is the most representative mutated gene in human 
fever-related epileptic syndromes. Patients with SMEI suffer from life-threatening status 
epilepticus, which is often provoked by fever, and patients with GEFS+ have repetitive 
FS that can persist beyond 6 years. Therefore, induction of appropriate treatments for 
FS in the early stages of onset is essential for these patients. 
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Rodent models harboring the responsible mutant genes are often used to elucidate 
the molecular pathogenesis and to cultivate novel treatments. Scn1a KO mice (Yu et al., 
2006; Ogiwara et al., 2007) and R1648H-Scn1a mice (Martin et al., 2010) were 
generated to investigate the SCN1A gene. Both types of heterozygous mutant mice 
exhibited susceptibility to hyperthermia-induced seizures (Oakley et al., 2009; Martin et 
al., 2010). Homozygous N1417H-Scn1a mutant rats in the present study also exhibited 
susceptibility to hyperthermia-induced seizures. 
In the present study, the effects of AEDs on hyperthermia-induced seizures were 
assessed in homozygous N1417H-Scn1a mutant rats. DZP and KBr showed potent 
effects on hyperthermia-induced seizures in these rats. DZP and KBr demonstrated 
reduction in the incidence of seizures, increase in the temperature threshold, and 
shortening of the seizure duration. Furthermore, DZP and KBr also decreased the 
duration of the seizure discharges on EEG. In the balance-beam test, DZP significantly 
increased the crossing time and total number of footfalls, whereas KBr did not 
demonstrate a significant effect on these parameters. Together with the blood level of 
each AED, these results suggested that DZP in low doses, but not KBr in high doses, 
influences motor coordination and balance. When the pharmacokinetics between DZP 
and KBr were compared, DZP was shown to be effective in the short term, whereas KBr 
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was shown to have a long half-life (12 days) in blood. Development of tolerance to DZP 
in long-term treatment is well known (Haigh and Feely, 1988). Since DZP is the first 
choice for treatment of status epilepticus because of its potent anticonvulsant effects, 
prolonged administration of DZP may decrease the effectiveness of stopping seizures in 
case of status epilepticus. Therefore, KBr may be recommended for repetitive FS. 
PB, VPA and TPM also showed efficacy for preventing hyperthermia-induced 
seizures. AZA and GBP decreased the seizure threshold but shortened the duration of 
seizures. However, the molecular mechanisms that induce hyperthermia-induced 
seizures and terminate seizures remain unknown. The results presented here suggest that 
the mechanisms that increase the seizure threshold and terminate seizures are different. 
Although AZA is mainly used for treating absence seizures, its ability to shorten 
seizures is remarkable. Hyperthermia-induced respiratory alkalosis involves the onset of 
hyperthermia-induced seizures (Schchmann et al., 2006), and metabolic acidosis 
terminates seizures and prevents seizure progression (Ziemann et al., 2008). AZA, a 
carbonic anhydrase inhibitor, is known to cause metabolic acidosis. In fact, AZA-Na 
(55 mg/kg) decreased the peripheral venous blood pH of rats from 7.38 ± 0.01 to 7.22 ± 
0.01 within 30 min of oral administration. This acidosis may have been partially 
responsible for decrease in the seizure duration in the AZA-treated group. These 
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findings suggest that AZA is useful for terminating prolonged seizures, but not for 
inhibiting seizure onset. 
Almost all AEDs have a partial effect on hyperthermia-induced seizures. CBZ, on the 
other hand, significantly reduced the seizure threshold, suggesting that CBZ may 
aggravate hyperthermia-induced seizures because of its sodium channel blocking effects 
(Macdonald et al., 2002).  
  Taken together, KBr and DZP are first-line treatments for hyperthermia-induced 
seizures in Scn1a mutant rats; PB, TPM and VPA are second-line treatments. It was 
observed that AZA suppressed and CBZ aggravated hyperthermia-induced seizures. 
However, how much of these results in the Scn1a mutant rats mimic the results of 
human epilepsy with SCN1A mutation? In patients with SMEI, of which more than 80% 
have a mutation in SCN1A, benzodiazepines and VPA are effective in preventing 
seizures (Ceulemans et al., 2004). KBr also improved generalized tonic-clonic seizures, 
generalized clonic seizures, and complex partial seizures (Oguni et al., 1994). KBr is 
known to induce several adverse effects such as drowsiness, headache, acneiform rashes, 
and loss of appetite. The significant toxicity associated with their use and the 
availability of safer AEDs may lead to a decrease in the use of KBr. The inhibitory 
effects of TPM as monotherapy were almost equal to those induced by VPA and PB. 
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The clinical efficacy of TPM as adjunctive therapy has been reported in SMEI patients 
(Nieto-Barrera et al., 2000, Coppola et al., 2002). Regarding the adverse effects of CBZ 
in the model rats, CBZ also aggravated seizures in patients with SMEI and GEFS+ 
(Guerrini et al., 1998; Horn et al., 1986). These reports in humans are consistent with 
the results presented here in the Scn1a mutant rats. Scn1a mutant rats seem to 
considerably reflect the pathogenesis of human SCN1A mutation-associated epilepsy. 
Considering the many differences, such as the way of treatment, treatment dose, type of 
seizure, age, gender, genetic background, and environmental factors, these rats may be 
useful for screening new AEDs or novel treatments for FS associated with SCN1A 
mutations in order to predict drugs that might be effective in human patients. 
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Figure Legends 
Figure 1. Hyperthermia-induced seizures in Scn1a mutant rats. (A) Hyperthermia was 
induced by placing the rats in a water bath filled with water at 45°C. (B) Head nodding 
and brief twitching movements were classified as a score of 1. (C) Repetitive myoclonic 
jerks of the forelimbs with a postural tone were classified as a score of 2. (D) Jumping 
and/or running fits were classified as a score of 3. (E) Generalized tonic-clonic seizures 
with loss of postural tone were classified as a score of 4. 
 
Figure 2. Comparison of effects of AEDs on hyperthermia-induced seizures in Scn1a 
mutant rats. (A) Suppression rate of seizures (%). (B) Temperature threshold. Rectal 
temperature of the rats was measured immediately after seizure onset (C) Seizure 
duration (D) Seizure severity score. Untreated (Cont., n = 9), VPA-Na (200 mg/kg, n = 
8), CBZ (200 mg/kg, n = 7), PB-Na (50 mg/kg, n = 7), GBP (100 mg/kg, n = 7), 
AZA-Na (55 mg/kg, n = 12), DZP (5 mg/kg, n = 7), TPM (80 mg/kg, n = 8), and KBr 
(1800 mg/kg, n = 7). Data are mean ± SEM. *p < 0.05, **p < 0.01 compared to controls 
(untreated). 
 
Figure 3. Representative ictal EEG patterns of a hyperthermia-induced seizure after 
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treatment with each AED. The top and bottom traces were from the frontal and occipital 
cortices, respectively. 
 
Figure 4. A representative ictal EEG of a hyperthermia-induced seizure from Scn1a 
mutant rats. (A) A Seizure began as tonic seizures (the first arrow) with high frequency 
spikes, followed by clonic seizures. Hyperthermia-induced seizures were often 
provoked as several recurrent seizures with a few seconds interval between the seizures. 
Before the second tonic seizure occurs (the second arrow), high amplitude spikes were 
associated with myoclonic jerks. The asterisk (*) indicates myoclonic jerks. After the 
termination of seizures, repetitive spikes continued for several seconds with no seizure 
manifestations (B) The duration of the seizure discharges between seizure onset (the 
first arrow) and termination (the third arrow) was measured. Untreated (Cont., n = 8), 
CBZ (200 mg/kg, n = 6), AZA-Na (55 mg/kg, n = 7), TPM (80 mg/kg, n = 6), DZP (5 
mg/kg, n = 8), and KBr (1800 mg/kg, n = 7). Data are mean ± SEM. *p < 0.05, **p < 
0.01 compared to controls (untreated). 
 
Figure 5. Balance-beam test apparatus for measuring motor coordination and balance. 
(A) A bright light was placed opposite the black box to encourage the rats to perform 
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the task. The time they took to cross the beam was recorded. (B) The number of times 
the hind limb slipped off the beam was counted. (C) Time to cross the beam after 
treatment with each AED. (D) Number of footfalls while crossing the beam after 
treatment with each AED. Untreated (Cont., n = 14), PB-Na (50 mg/kg, n = 15), 
AZA-Na (55 mg/kg, n = 14), DZP (5 mg/kg, n = 7), and KBr (1800 mg/kg, n = 10). 
Data are mean ± SEM. *p < 0.05, **p < 0.01 compared to controls (untreated). 
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Table 1. Blood concentrations of antiepileptic drugs immediately after 
hyperthermia-induced seizures in Scn1a mutant rats. 
 n 
Dose 
(mg/kg) 
Blood level 
(µg/ml) 
Therapeutic range 
(µg/ml) 
References 
VPA 8  200   174.7 ± 22.8 40–120 Schmidt, 2009 
CBZ 7  200   13.2 ± 1.7 4–12 Eadie, 2001 
PB-Na 7  50   40.3 ± 0.8 12–30 Schmidt, 2009 
GBP 7  100   33.5 ± 1.4 2–20 McLean, 1999 
AZA-Na 12  55   49.8 ± 4.0 10–20 Granero et al., 2007 
DZP 7  5   0.15 ± 0.04 0.2–0.6 Ogutu et al., 2002 
TPM 8  80   n.d. — — 
KBr 7  1800   1769.1 ± 204.7 500–1500 Ryan and Baumann, 1999 
Data are mean ± SEM.
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